New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
09:25 EDTAVTH, AVTH, SSET, SSET, AWK, AWK, NBS, NBS, SNWV, SNWV, ATNM, ATNM, VTEQ, VTEQ, AKER, AKER, CGIX, CGIX, DIRI, DIRIRedChip Companies to hold a virtual conference
Global Online CEO Conference to be held on July 16-17 with webcasted presentations to begin on July 16 at 9:30 am. Webcast Link
News For AVTH;CGIX;AKER;VTEQ;ATNM;SNWV;NBS;AWK;SSET;DIRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
14:12 EDTAWKMaryland American Water files request for rate increase
Subscribe for More Information
December 18, 2014
07:13 EDTAKERAkers signs EU distribution agreements for PIFA Heparin/PF4 Rapid Assay products
Subscribe for More Information
December 15, 2014
07:32 EDTAWKAmerican Water sees FY15 continuing ops EPS $2.55-$2.65
Subscribe for More Information
December 10, 2014
07:18 EDTAKERAkers Biosciences announces $1M initial order to supply PIFA Heparin PF4
Subscribe for More Information
December 9, 2014
07:32 EDTCGIXCancer Genetics to receive $530,000 through NJ Technology Business Tax Program
Cancer Genetics announced that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
07:14 EDTATNMActinium Pharmaceuticals SAB endorses Iomab-B Phase 3 clinical trials
Subscribe for More Information
December 8, 2014
15:54 EDTAWKAmerican Water to host conference call
Subscribe for More Information
07:37 EDTCGIXCancer Genetics announces launch of sequencing based panel for CLL
Cancer Genetics announced it has been licensed by the Clinical Laboratory Improvement Amendments to perform Focus::CLL, the company's unique next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma. The panel assesses seven genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes.
07:35 EDTNBSNeoStem earns AABB re-accreditation for NJ manufacturing facility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use